# HQY earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/HQY) · [Earnings tab](https://www.lopjlb.com/stock/HQY?tab=earnings)

Updated: 2026-08-29T05:29:52

Quarters analyzed: 8

## Cross-quarter narrative

Across 8 calls for HQY, management tone moved from +0.60 (2025 Q3) to +0.80 (2027 Q2). Latest guidance stance: vague. Latest desk line: HealthEquity Q2 FY27: revenue growth accelerates to 8%, adj EBITDA margin hits record 48%, guidance raised; HSA accounts reach 10.7M, marketplace surpasses 14k active members, AI drives 25% call reduction and service cost declines.

## Latest CallCard · Q2

HealthEquity Q2 FY27: revenue growth accelerates to 8%, adj EBITDA margin hits record 48%, guidance raised; HSA accounts reach 10.7M, marketplace surpasses 14k active members, AI drives 25% call reduction and service cost declines.

**Guidance:** vague

**Tone:** mgmt 0.8 · Q&A pressure 0.4 · divergence 0.4

Management highlights accelerated revenue growth, record profitability, raised guidance, strong account growth, AI-driven efficiency gains, and durable model scaling.

## Quarter one-liners

- **2027 Q2:** HealthEquity Q2 FY27: revenue growth accelerates to 8%, adj EBITDA margin hits record 48%, guidance raised; HSA accounts reach 10.7M, marketplace surpasses 14k active members, AI drives 25% call reduction and service cost declines.
- **2027 Q1:** HealthEquity Q1 FY2027 shows higher profitability, raised guidance, strong HSA growth, AI‑driven cost cuts and marketplace expansion, while noting modest cash and ongoing AI investment uncertainties.
- **2026 Q4:** HealthEquity posted record HSA sales, strong margin expansion and raised FY2027 guidance, highlighting AI‑driven efficiency, a new marketplace and early ACA‑driven retail growth while maintaining share buybacks and debt reduction.
- **2026 Q3:** —
- **2026 Q2:** HealthEquity posted strong Q2 growth, raised FY2026 guidance and highlighted AI, mobile security, and new HSA legislative opportunities while noting macro employment headwinds.
- **2026 Q1:** HealthEquity posted strong Q1 FY2026 growth, raised FY guidance, highlighted fraud cost reductions, mobile‑first security push and potential HSA legislative expansion, while noting macro slowdown and legislative uncertainty.
- **2025 Q4:** —
- **2025 Q3:** HealthEquity posted double‑digit Q3 growth, raised FY25 guidance, highlighted HSA expansion and tech initiatives, while noting fraud‑related costs and uncertainty around legislative and yield outlooks.

## Theme arcs

- **Management tone** (improving): Δ mgmt=+0.20

## Fear persistence

- **legislative risk** [recurring]: 2025 Q3, 2026 Q2
- **yield risk** [resolved]: 2025 Q3
- **asset maturity risk** [resolved]: 2025 Q3
- **fraud risk** [recurring]: 2025 Q3, 2026 Q1, 2026 Q2
- **competitive pressure** [recurring]: 2025 Q3, 2026 Q1, 2026 Q2, 2027 Q1
- **macroeconomic risk** [resolved]: 2025 Q3
- **technology implementation risk** [resolved]: 2025 Q3
- **guidance uncertainty** [resolved]: 2025 Q3
- **macro slowdown** [resolved]: 2026 Q1
- **legislative uncertainty** [resolved]: 2026 Q1

## Guidance path

2025 Q3:raised → 2025 Q4:vague → 2026 Q1:raised → 2026 Q2:raised → 2026 Q3:vague → 2026 Q4:raised → 2027 Q1:raised → 2027 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/HQY`